{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:48Z","timestamp":1792511508315,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020171","name":"Foreign, Commonwealth and Development Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627004"],"award-info":[{"award-number":["JP223fa627004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"United Kingdom Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jvacx.2023.100321","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T22:35:51Z","timestamp":1686263751000},"page":"100321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: A modelling study"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-0884","authenticated-orcid":false,"given":"George Y.","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Jombart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"John Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jvacx.2023.100321_b0005","doi-asserted-by":"crossref","first-page":"e1000536","DOI":"10.1371\/journal.ppat.1000536","article-title":"Isolation of genetically diverse Marburg viruses from Egyptian fruit bats","volume":"5","author":"Towner","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jvacx.2023.100321_b0010","doi-asserted-by":"crossref","unstructured":"Slenczka W, Klenk HD. Forty years of marburg virus. J Infect Dis. 2007 Nov 15;196 Suppl 2:S131-135.","DOI":"10.1086\/520551"},{"key":"10.1016\/j.jvacx.2023.100321_bib52","doi-asserted-by":"crossref","unstructured":"Qian GY, Edmunds WJ, Bausch DG, Jombart T, Modelling Vaccination Strategies for the Control of Marburg Virus Disease Outbreaks | medRxiv [Internet]. [cited 2023 Jan 13]. Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.06.17.22276538v2.full-text.","DOI":"10.1101\/2022.06.17.22276538"},{"issue":"9","key":"10.1016\/j.jvacx.2023.100321_b0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJMoa051465","article-title":"Marburg hemorrhagic fever associated with multiple genetic lineages of virus","volume":"355","author":"Bausch","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jvacx.2023.100321_b0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.spid.2005.05.001","article-title":"Outbreak of Marburg Hemorrhagic Fever in Angola: A Review of the History of the Disease and its Biological Aspects","volume":"16","author":"Ligon","year":"2005","journal-title":"Semin Pediatr Infect Dis"},{"issue":"10088","key":"10.1016\/j.jvacx.2023.100321_b0025","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/S0140-6736(17)31635-5","article-title":"WHO R&D Blueprint: a global coordination mechanism for R&D preparedness","volume":"389","author":"Kieny","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2023.100321_b0030","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). RV 507: A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Marburg Chimpanzee Adenovirus Vector Vaccine, VRC-MARADC087-00-VP (cAd3-Marburg), in Healthy Adults [Internet]. clinicaltrials.gov; 2022 Aug [cited 2023 Jan 11]. Report No.: NCT03475056. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03475056."},{"issue":"6","key":"10.1016\/j.jvacx.2023.100321_b0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/17407745221110880","article-title":"A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats","volume":"19","author":"Longini","year":"2022","journal-title":"Clin Trials Lond Engl"},{"issue":"10068","key":"10.1016\/j.jvacx.2023.100321_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jvacx.2023.100321_b0045","doi-asserted-by":"crossref","first-page":"e41785","DOI":"10.1371\/journal.pone.0041785","article-title":"An Assessment of the Screening Method to Evaluate Vaccine Effectiveness: The Case of 7-Valent Pneumococcal Conjugate Vaccine in the United States","volume":"7","author":"Cohen","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jvacx.2023.100321_b0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1473-3099(18)30164-6","article-title":"Impact of enhanced viral haemorrhagic fever surveillance on outbreak detection and response in Uganda","volume":"18","author":"Shoemaker","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136223000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:30:29Z","timestamp":1792510229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136223000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":11,"alternative-id":["S2590136223000621"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100321","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.22.23286294","asserted-by":"object"}]},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: A modelling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2023.100321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100321"}}